Paclitaxel (Taxol®): A success story with valuable lessons for natural product drug discovery and development

Medicinal Research Reviews

Volumn 18, Issue 5, 1998, Pages 315-331

  Cragg, Gordon M ^a,b,c,d,e,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RHODES UNIVERSITY   (South Africa)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTH AFRICA   (South Africa)

^f ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Mechanisms of action; Multidisciplinary collaboration; Novel screens; Supply

Indexed keywords

BRYOSTATIN 1; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; MAYTANSINE; MITOFLAXONE 2 DIETHYLAMINOETHYL ESTER; PACLITAXEL; RHIZOXIN; TEROXIRONE; VINBLASTINE SULFATE; VINCRISTINE SULFATE; ZINOSTATIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; DATA BASE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW; TEAMWORK; CELL CULTURE; COOPERATION; DRUG DESIGN; ISOLATION AND PURIFICATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; COOPERATIVE BEHAVIOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0031595885     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.0.CO;2-W     Document Type: Review

References (35)

1. G. M. Cragg, D. J. Newman, and K. M. Snader, J. Nat. Prod., 60, 52 (1997).
2. J. L. Hartwell and A. W. Schrecker, in Progress in the Chemistry of Organic Natural Products, L. Zechmeister, Ed., Springer-Verlag, Vienna, Austria, 15, 83 (1958).
3. I. Jardine, in Anticancer Agents Based on Natural Products Models, J. M. Cassady and J, D. Douros, Eds., Academic Press, New York, 1979, p. 319.
4. I. S. Johnson, H. F. Wright, and G. H. Svoboda, Proc. Am. Assoc. Cancer Res., 3, 122 (1960).
5. S. K. Carter and R. B. Livingston, Cancer Treat. Rep., 60, 1141 (1976).
6. J. S. Driscoll, Cancer Treat. Rep., 68, 63 (1984).
7. J. M. Venditti, R. A. Wesley, and J. Plowman, Adv. Pharmacol. Chemotherapeutics, 20, 1 (1984).
8. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon, and A. T. McPhail, J. Am. Chem. Soc., 93, 2325 (1971).
9. J. J. Manfredi and S. B. Horwitz, Pharmacol. Ther., 25, 83 (1984).
10. J. P. Davignon and J. C. Cradock, in Principles of Chemotherapy, S. K. Carter and K. Hellman, Eds., Mc-Graw-Hill, Inc., New York, 1987, p. 212.
11. M. Lassus, D. Scott, and B. Leyland-Jones, Proc. Am. Soc. Clin. Oncol., 4, 268 (1985).
12. E. K. Rowinsky, L. A. Cazenave, and R. C. Donehower, J. Nat. Cancer Inst., 82, 1247 (1990).
13. W. P. McGuire, E. K. Rowinsky, N. B. Rosenheim, F. C. Grumbine, D. S. Ettinger, D. K. Armstrong, and R. C. Donehower, Annals of Internal Medicine, 111, 273 (1989).
14. F. A. Holmes, R. S. Walters, R. L. Thierault, A. D. Forman, L. K. Newton, M. N. Raber, A. U. Buzdar, D. K. Frye, and G. N. Hortobagyi, J. Natl. Cancer Inst., 83, 1797 (1991).
15. A. Seidman, B. Reichman, J. Crown, C. Begg, R. Heelan, T. Hakes, A. Surbone, T. Gilewski, D. Lebwohl, V. Currie, C. Hudis, R. Klecker, J. Collins, F. Toomasi, R. Berkery, S. Quinlivan, D. Kelsen, and L. Norton, Proc. Am. Soc: Clin. Oncol., 11, 64 (1992).
16. J. Fisherman, M. McCabe, M. Hillig, B. Goldspiel, K. H. Cowan, and J. O'Shaughnessy, Proc. Am. Soc. Clin. Oncol., 11, 54 (1992).
17. A. Chang, K. Kim, J. Glick, T. Anderson, D. Karp, and D. Johnson. Proc. Am. Soc. Clin. Oncol., 11, 981 (1992).
18. A. A. Forestiere, D. Neuberg, S. G. Taylor, R. DeConti, and G. Adams. Monogr. Natl. Cancer Inst., 15, 181 (1993).
19. A. I. Einzig, H. Hochster, P. H. Wiernik, D. L. Trump, J. Dutcher, E. Garowski, J. Sasloff, and T. J. Smith, Invest. New Drugs, 9, 59 (1991).
20. W. H. Wilson, S. Berg, Y. K. Kang, S. Bates, A. Fojo, S. Steinberg, F. Balis, B. Goldspiel, J. O'Shaughnessy, B. A. Chabner, and R. E. Wittes, Proc. Am. Soc. Clin. Oncol., 12, 134 (abstr.) (1993).
21. G. M. Cragg, S. A. Schepartz, M. Suffness, and M. R. Grever, J Nat. Prod., 56, 1657 (1993).
22. S. G. Arbuck and B. A. Blaylock, in Taxol® Science and Applications, M. Suffness, Ed., CRC Press Inc., Boca Raton, FL, 1995, Chap. 14, p. 379.
23. M. R. Boyd and K. D. Paull, Drug Development Research, 34, 91 (1995).
24. M. Potmesil and H. Pinedo, Camptothecins: New Anticancer Agents, CRC Press, Inc., Boca Raton, FL, 1995.
25. K. D. Paull, R. H. Shoemaker, L. Hodes, A. Monks, D. A. Scudiero, L. Rubinstein, J. Plowman, and M. R. Boyd, J. Natl. Cancer Inst., 81, 1088 (1989).
26. K. D. Paull, E. Hamel, and L. Malspeis, in Cancer Chemotherapeutic Agents, O. Foye, Ed., ACS Professional Reference Book, American Chemical Society, Washington, D.C., 1995, Chap. 2, p. 9.
27. J. N. Denis, A. E. Green, D. Guénard, F. Guéritte-Voegelein, L. Mangatal, and P. Potier. J. Amer. Chem. Soc., 110, 5917 (1988).
28. J. E. Cortes and R. Pazdur, J. Clin. Oncol., 13, 2643 (1995).
29. I. Anderson and B. Holmes, New Scientist, November 25, 5 (1995).
30. G. R. Pettit, D. Sengupta, P. M. Blumberg, N. E. Lewin, J. M. Schmidt, and A. S. Kraft, Anti-cancer Drug Design, 7, 101 (1992).
31. D. E. Schaufelberger, M. P. Koleck, J. A. Beutler, A. M. Vatakis, A. B. Alvarado, P. Andrews, L. V. Marzo, G. M. Muschik, J. Roach, J. T. Ross. W. B. Lebherz, M. P. Reeves, R. M. Eberwein, L. L. Rodgers, R. T. Testerman, K. M. Snader, and S. Forenza, J. Nat. Prod., 54, 1265 (1991).
32. D. Mendola, C. J. Sheehan, and B. J. Javor, Poster Presentation, Marine Natural Products Gordon Research Conference, Ventura, CA, February 25, 1996.
33. M. Suffness, G. M. Cragg, M. R. Grever, F. J. Grifo, G. Johnson, J. A. R. Mead, S. A. Schepartz, J. M. Venditti, and M. Wolpert, Internat. J. Pharmacognosy, 33, Suppl., 5 (1995).
34. J. Rosenthal, Proceedings of the Organisational for Economic and Commercial Development: Investing in Biological Diversity, The Cairns Conference, Australia, 25-28 March, 1996, OECD Publications, Paris, 1997, p. 253.
35. T. D. Mays and K. D. Mazan, J. Ethnopharmacology, 51, 93 (1996).